Mesothelioma cancer patients may benefit from new research that sheds light onto the reason behind the growth of these tumour cells which, unlike most cancers, have no oncogenic drivers.

Scientists from the MRC Toxicology Unit (University of Cambridge) and the CRUK Beatson Institute (University of Glasgow) worked on the research just published in Nature Communications. It explores the role of the protein synthesis machinery in tumour growth and provides insights into a new therapeutic target that could extend the life of patients with this disease.

Read the full press release here.